Royalty Report: Medical, Device, Ophthalmological – Collection: 26782


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Medical
  • Device
  • Ophthalmological
  • Surgical
  • Supply
  • Eye Surgery Procedure
  • Drugs
  • Pharmaceuticals
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26782

License Grant
The U.S. Licensor hereby grants to Swiss Licensee an exclusive license under the Patent Rights, Know How and Trademarks, to make, have made, use, and sell Products in the Territory.
License Property
'PRODUCTS' shall mean ophthalmic medical devices used in the treatment of presbyopia, hyperopia, ocular hypertension and glaucoma, the manufacture, use or sale of which, would, but for this Agreement, constitute or would result in an infringement of the Patent Rights in any country including, but not limited to, the products set forth in the attached SCHEDULE B and any enhancements or improvements thereto.

Licensor's primary products are the patented PresVIEW device and the related PresVIEW Incision System, the automated surgical instrument for the surgical treatment of Presbyopia, Ocular Hypertension and Primary Open Angle Glaucoma, or POA Glaucoma, in the human eye.

The PresVIEW device consists of four separate tiny plastic segments, each about the size of a grain of rice, made from polymethylacrylate, or PMMA. PMMA has been implanted in the eye for other types of surgical procedures (intraocular lenses, hard contact lenses) for over fifty years. The surgeon uses the PresVIEW Incision System to make four superficial incisions in the quadrants of the sclera (white of the eye). The PresVIEW device is inserted into the superficial tunnels, causing a lift in the sclera that in turn reduces the crowding of the underlying muscles.

The full royalty rate schedule has not been made public, the only publicly available rate is a know-how royalty rate for countries where a relevant patent has expired.

Field of Use
The rights granted apply to the human eye.

IPSCIO Record ID: 1513

License Grant
The Company hereby grants a world-wide, nonexclusive, nontransferable, royalty-bearing license to use the Licensed Patents to manufacture, have manufactured, sell, distribute and market the Licensed Products (soft intraocular lens products) and to practice the inventions covered by the Licensed Patents.
License Property
Licensed Products shall mean any intraocular lens products, and devices used to insert and/or apply the intraocular lens products, made, used or sold for use in a manner which is covered by a Valid Patent Claim of the Licensed Patents. Patent No. 4,573,998 Methods for Implantation of Deformable Intraocular Lenses; Patent No. 4,715,373 Devices for implantation of Deformable Intraocular Lens Structures; Patent No. 4,702,244 Surgical Device for Implantation of a Deformable Intraocular Lens.
Field of Use
The rights granted apply to implantation of lenses.

IPSCIO Record ID: 159683

License Grant
Licensor hereby grants to Licensee and its Affiliates, upon the terms and conditions herein specified, a worldwide non-exclusive license under the Licensed Technology and the Licensed Patent. There is no right to sublicense included in this grant.
License Property
Licensed Patent shall mean United States Patent No. 4,573,998 and any corresponding foreign patent applications or patents issued March 4, 1986, and entitled Methods for Implantation of Deformable Intraocular Lenses and any reissue thereof.
Field of Use
This agreement pertains to the medical industry in relation to intraocular lens structures.

IPSCIO Record ID: 4411

License Grant
The assignment of the intellectual property agreement for International Patent Application No. PCT/IB2010/000797 to Licensee, the Hong Kong affiliate.
License Property
PCT/IB2010/000797 A Device and Method for Lifting Abdominal Wall During Medical Procedure

IPSCIO Record ID: 4911

License Grant
Licensor grants to Licensee an exclusive, worldwide, license, with the right to grant sublicenses, under Licensor Patents and Know-how to make, have made, use, import, offer for sale and sell the Catarex Products in the Licensee Field.
License Property
Licensor has developed a proprietary surgical instrument system designed to improve the removal of human cataracts, which instrument is generally referred to as Catarex-TM.

Catarex removes the lens nucleus and cortex in a single step through a small incision in the eye while leaving the lens capsule functionally intact.

Field of Use
Licensee Field means all applications of Catarex Products for human ophthalmic surgery.

IPSCIO Record ID: 1928

License Grant
The Company entered into a license Agreement with Chairman of the Board and other doctor for the Iris Expander minimally invasive ocular device.
License Property
The now patented device, made from expansive hydrogel polymers, is inserted through a small incision in the cornea.  It rapidly expands to a predetermined size and holds the iris back while surgery takes place.
Field of Use
The rights granted apply to the healthcare industry relating to the eye.

IPSCIO Record ID: 375422

License Grant
The Settling Parties agreed to terminate the patent infringement lawsuit the Plaintiff had filed against the defendant on April 14, 2018 in the U.S. District Court for the Central District of California, Southern Division (the Lawsuit).
License Property
In the Lawsuit, the Plaintiff alleged that the Defendants Hydrus® Microstent device infringes the Company’s U.S. Patent Nos. 6,626,858 and 9,827,143.
6,626,858 – Shunt device and method for treating glaucoma
9,827,143 – Shunt device and method for treating ocular disorders
Field of Use
The medical device is for the treatment of eye disorders such as glaucoma and ocular.

IPSCIO Record ID: 317633

License Grant
The Company and an executive of the Company entered into a Royalty Agreement wherein the Company agreed to pay the executive a royalty on a product-by-product basis for certain proprietary information and inventions that were patented during his employment with the Company.
License Property
Proprietary information and inventions include but not limited to the products such as Lucent Lateral Interbody Implant System, the Lucent XP Expandable Interbody Device System, the Clutch ISP Posterior Fixation System, the Karma Fixation System, the Vertu Anterior Stand-Alone System and Mosaic devices.

The product portfolio addresses a broad spectrum of spine surgery procedures and consists of innovative spinal fixation systems (implantable hardware systems that are mechanically attached to the spine and provide stability), interbody implants (devices implanted between the vertebral bodies of the spine), surgical instruments (instruments used to prepare the spine and implant our devices) and biologics (allograft or synthetic biomaterials intended to augment or replace the normal capacity of such tissue in the body).

“Product Line” shall mean each of the following product categories, with each understood to specifically contain and be solely composed of the individual products and parts set forth on Schedule A (i) Mosaic, (ii) Vertu, (iii) Lucent Lateral, (iv) Lucent Expandable, (v) ISP (Clutch), and (vi) Zip Tie (Karma).

Field of Use
The field of use is for the procedures used in surgery with reduced trauma to the muscles and soft tissues, less blood loss, smaller incisions, shorter procedure time, reduced hospitalization, lower post-operative medication use, faster patient recovery and other benefits for patients and surgeons.

The Company is a medical device company focused on the design, development and commercialization of a comprehensive portfolio of systems, products and technologies for spine surgery procedures, with a strategic focus on minimally invasive surgery (“MIS”) procedures.

IPSCIO Record ID: 1514

License Grant
The license was granted for use on the exclusive territory to the Swiss Licensee by the Russian Licensor.
License Property
Licenser possesses the 'Technology for Producing Collagen-Based Cross-Linked Drain', and the Licensiate wants to acquired the license on this technology. Technology of production intraocular lenses from collagen co-polimers.   Artificial eye lenses, which are implantated through small sizes, are most perspective.  Several requirements are produced to artificial eye lenses like elasticity, biocompatibility, low specific density and high solidity on rupture.  Artificial eye lenses from collagen co-polimers corresponds to these principles.

Technology of production intraocular lenses from collagen co-polimers Nowadays, intraocular correction is one of the basic medical treatment method of vision body disease.
Artificial eye linses are used not only when cataract, but also for removal of refraction anomalies.
Artificial eye lenses, which are implantated through small sizes, are most perspective. Several requirements are produced to artificial eye lenses like elasticity, biocompatibility, low specific density and high solidity on rupture. Artificial eye lenses from collagen co-polimers corresponds to these principles.
Highest elasticity, hight solidity on rupture are the main quality of these products. It allows to make implantation as tool-making method of injection also.
Lenses, which are maked an special technology, passed experimental and hospital tests successfully and inculcated in wide surgical practice as in Eye Microsurgery Intersectoral Research and Technology Complex so in the other Russian and CIS hospitals.

US patent N 6.286.829 (Russion application N 4745668) 'Biocompatible polymer material and a process for producing same'
USA patent N 5258025 (Russian application N 4881670) 'correctional intraocular lens'

IPSCIO Record ID: 26503

License Grant
Pursuant to the License Agreement, the Company granted a license to certain patents owned or licensed by the Company in the field of presbyopia and certain ophthalmology patents.
License Property
Presbyopia is a condition affecting nearly every individual over 40 in which there is a decline in unaided near-distance sight.
Field of Use
Presbyopia Field of Use shall mean laser treatment of presbyopia, including any inherent and/or coincident, related procedures and benefits.

Ophthalmology Field of Use shall mean the medical specialty encompassing the anatomy, functions, pathology and treatment of the eye.

IPSCIO Record ID: 5827

License Grant
The Company entered into a Patent License Agreement to obtain the exclusive license to U.S. Patent No.08/781,504 and No. 6,059,772.
License Property
DeepLight®790 is a medical device system for the treatment of glaucoma.

IPSCIO Record ID: 5171

License Grant
This option when exercised will grant on a product-by-product and country-by-country basis, including the attainment of a perpetual, exclusive license, with the right to sublicense, to research, develop, make, have made and use some of the Product(s).
License Property
The products relate to eyecare and chronic pain. Some applications are related to Glaucoma treatment.

Brimo Timolol Combo          Eyecare                  Ocular Hypertension/Primary Angle Glaucoma
Keto Reformulation             Eyecare                  Post surgical Pain
Alpha 2 Pain                       New Technologie   Chronic Pain
Photo Dynamic Therapy     Eyecare                  Age Related Macular Degeneration
AGN 195795                      Eyecare                  Glaucoma

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.